[1]侯晓杰.免疫治疗药物对非小细胞肺癌的有效性和安全性研究[J].医学信息,2022,35(18):118-120.[doi:10.3969/j.issn.1006-1959.2022.18.032]
　HOU Xiao-jie.Study on the Efficacy and Safety of Immunotherapy Drugs for Non-small Cell Lung Cancer[J].Journal of Medical Information,2022,35(18):118-120.[doi:10.3969/j.issn.1006-1959.2022.18.032]
点击复制

免疫治疗药物对非小细胞肺癌的有效性和安全性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
118-120
栏目:
药物与临床
出版日期:
2022-09-15

文章信息/Info

Title:
Study on the Efficacy and Safety of Immunotherapy Drugs for Non-small Cell Lung Cancer
文章编号:
1006-1959（2022）18-0118-03
作者:
侯晓杰
（1.青岛大学基础医学院，山东 青岛 266071；2.临沂市中心医院高压氧科，山东 临沂 276400）
Author(s):
HOU Xiao-jie
(1.School of Basic Medicine,Qingdao University,Qingdao 266071,Shaanxi,China;2.Hyperbaric Oxygen Department of Linyi Central Hospital,Linyi 276400,Shandong,China)
关键词:
免疫治疗; 非小细胞肺癌; 卡瑞利珠单抗; 血管内皮生长因子; 肿瘤标志物
Keywords:
Immunotherapy; Non-small cell lung cancer; Carrelizumab; Vascular endothelial growth factor; Tumor markers
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2022.18.032
文献标志码:
A
摘要:
目的 研究免疫治疗药物治疗非小细胞肺癌的有效性和安全性。方法 选取2018年9月-2021年9月在我院诊治的86例非小细胞肺癌患者为研究对象，采用随机数字表法分为对照组和观察组，各42例。对照组采用顺铂+多西他赛治疗，观察组在对照组基础上联合卡瑞利珠单抗治疗，比较两组临床疗效、血管内皮生长因子（VEGF）、血清肿瘤标志物水平、毒副反应发生率。结果 观察组治疗总有效率为71.43%，高于对照组的57.14%（P＜0.05）；两组治疗后VEGF均低于治疗前，且观察组低于对照组（P＜0.05）；治疗后两组糖类抗原125（CA125）、糖类抗原199（CA199）、癌胚抗原（CEA）均低于治疗前，且观察组低于对照组（P＜0.05）；观察组毒副反应发生率为52.83%，与对照组的50.00%比较，差异无统计学意义（P＞0.05）。结论 免疫治疗药物治疗非小细胞肺癌可提高治疗总有效率，降低血清肿瘤标志物水平，且不良反应少，具有重要的临床应用价值。
Abstract:
Objective To study the efficacy and safety of immunotherapy drugs in the treatment of non-small cell lung cancer.Methods A total of 86 patients with non-small cell lung cancer diagnosed and treated in our hospital from September 2018 to September 2021 were selected as study subjects. They were divided into control group and observation group according to random number table method, with 42 cases in each group. The control group was treated with cisplatin+docetaxel, and the observation group was treated with carrelizumab on the basis of the control group. The clinical efficacy, vascular endothelial growth factor (VEGF), serum tumor marker levels, and incidence of toxic and side effects were compared between the two groups.Results The total effective rate of the observation group was 71.42%, which was higher than 57.14% of the control group (P<0.05). VEGF in the two groups after treatment was lower than before treatment, and the observation group was lower than the control group (P<0.05). After treatment, carbohydrate antigen 125 (CAl25), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) in the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). The incidence of side effects in the observation group was 52.83%, compared with 50.00% in the control group, and the difference was not statistically significant (P>0.05).Conclusion Immunotherapy drugs for non-small cell lung cancer can improve the total effective rate of treatment, reduce the level of serum tumor markers, and have fewer adverse reactions, which has important clinical application value.

参考文献/References:

[1]Hida T,Nokihara H,Kondo M,et al.Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer( J-ALEX):An open-label,randomised phase 3 trial[J].Lancet,2017,390(10089):29-39.[2]孔君,杨雪,孔辉,等.2394例肺腺癌患者EGFR及ALK驱动基因分析[J].南京医科大学学报(自然科学版),2020,40(5):675-680.[3]师志云,郭雅琪,江海峰,等.宁夏某医院225例非小细胞肺癌患者EGFR基因突变检测结果分析[J].检验医学与临床,2020,17(10):1324-1327.[4]乔秀丽,艾丹,梁洪陆,等.山东地区非小细胞肺癌分子靶向治疗驱动基因表达情况及临床特征分析[J].中国肺癌杂志,2017,20(1):14-20.[5]Kim R,Keam B,Hahn S,et al.First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: A systematic review and network meta- analysis[J].Clin Lung Cancer,2019,20(5):331-338.e4.[6]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2019[M].北京:人民卫生出版社,2019.[7]黄德良,姚中平,张卫忠.PD-1抑制剂派姆单抗对晚期非小细胞肺癌T淋巴细胞亚群及NK细胞的影响[J].国际肿瘤学杂志,2017,44(3):122-125.[8]刘雷,丁琛琛,胡胜,等.非小细胞肺癌免疫功能与TKI治疗疗效的关系[J].中国肿瘤,2016,25(10):811-815.[9]赵美玲,蔡小华,杨方方,等.ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察[J].广州医药,2017,48(5):57-60.[10]赵海燕,苏乌云,呼群,等.DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及对免疫功能的影响[J].现代生物医学进展,2017,17(13):2560-2564.[11]胡振红,吴妍雯,刘海潮,等.过继免疫联合化疗对晚期非小细胞肺癌的疗效及免疫功能的影响[J].实用癌症杂志,2016,31(9):1466-1469.[12]白璐,李莉红,梁晶.免疫疗法联合EGFR-TKI治疗EGFR突变晚期非小细胞肺癌恶性程度评估[J].海南医学院学报,2017,23(8):1109-1112.[13]周洋媚,杨丽,孙伟,等.含贝伐珠单抗化疗方案对转移性非小细胞肺癌患者血小板的影响[J].肿瘤药学,2018,8(2):170-173.[14]齐晓光,祁春艳,王李杰,等.非小细胞肺癌基因突变量与PD1单抗疗效关系的分析[J].现代肿瘤医学,2018,26(19):3073-3076.[15]杨现松.尼妥珠单抗靶向治疗联合放化疗对晚期非小细胞肺癌近期疗效及外周血淋巴细胞亚群的影响[J].山东医药,2016,56(33):94-96.[16]潘敏,赵爽,彭雪梅,等.免疫治疗联合化疗在中晚期非小细胞肺癌治疗中的应用效果研究[J].癌症进展,2016,14(6):587-590.[17]鲁广,夏冰,柴枫,等.尼妥珠单抗联合三维适形放射治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016,36(2):245-249.[18]Chen DS,Mellman I.Elements of cancer immunity and the cancer-immune set point[J].Nature,2017,541( 7637):321-330.[19]陈刚,邬冬强.贝伐珠单抗注射液辅助治疗老年局部非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(21):1967-1970.[20]纪春东,于秀芹,赖永新.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J].河北医学,2017,23(1):100-102.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(18):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(18):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(18):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
　CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Journal of Medical Information,2019,32(18):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
[9]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(18):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[10]刘 丽,孙立新,赵明珍,等.干扰素-γ对乳腺癌细胞HLA-Ⅰ分子表达的影响[J].医学信息,2019,32(04):88.[doi:10.3969/j.issn.1006-1959.2019.04.029]
　LIU Li,SUN Li-xin,ZHAO Ming-zhen,et al.Effect of Interferon-γ on HLA-Ⅰ Expression in Breast Cancer Cells[J].Journal of Medical Information,2019,32(18):88.[doi:10.3969/j.issn.1006-1959.2019.04.029]
[11]刘 垚,钱有辉.ctDNA检测及靶向药物在非小细胞肺癌中的应用[J].医学信息,2020,33(11):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
　LIU Yao,QIAN You-hui.Detection of ctDNA and Application of Targeted Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2020,33(18):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
[12]王 超.非小细胞肺癌免疫治疗的研究[J].医学信息,2021,34(11):57.[doi:10.3969/j.issn.1006-1959.2021.11.017]
　WANG Chao.Research on Immunotherapy of Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(18):57.[doi:10.3969/j.issn.1006-1959.2021.11.017]
[13]韩 寒,陈雨晨,刘 洋,等.替雷利珠单抗治疗晚期非小细胞肺癌患者的真实世界研究[J].医学信息,2025,38(08):80.[doi:10.3969/j.issn.1006-1959.2025.08.016]
　HAN Han,CHEN Yuchen,LIU Yang,et al.A Real-world Study of Tislelizumab in the Treatment of Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2025,38(18):80.[doi:10.3969/j.issn.1006-1959.2025.08.016]

更新日期/Last Update: 1900-01-01